Report Store Get Proposal

Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports. Check Now!

Home Blog Oncology 5

Oncology

pharma-news-for-gilead-merck-astellas

Notizia - Recent Pharma, Healthcare and Biotech Happenings

Gilead and Merck Announce Encouraging Phase II Results of Islatravir and Lenacapavir Combo; REGENXBIO Highlights Positive Data from Phase II ABBV-RGX-314 Wet AMD Study at AAO 2024; FDA Greenlights Astellas’ VYLOY for Advanced Gastric and GEJ Cancer Therapy; Merck’s CAPVAXIVE Vaccine Yields Strong Immune Response in Adults Vulnerable to Pneumococcal Disease; FDA Postpones LUMAKRAS Colorectal Cancer Verdict to Early 2025

Gilead and Merck Reports Phase II Data Showing that Switching to a Once-Weekly Oral Combination of Islatravir and Lenacapavir Maintained Viral Suppression in Adults Through 48 Weeks Gilead Sciences, Inc. and Merck have shared new findings from a Phase II clinical trial assessing the experimental combination of islatravir, a novel nucleoside reverse transcriptase translocation inhibitor, and lenacapavir, a pioneering HIV-1 capsid inhibitor. These significant results were presented during an oral session at IDWeek 2024, held in Los Angeles and online from October 16-19. At 48 weeks, the new investigational combination achieved a high viral suppression rate (n=49; ...

Explore More...

crisis-impacting-bladder-cancer-treatment

Imbalance Between BCG Supply and Increased Demand: The Crisis Impacting Bladder Cancer Treatment

Pharma-news-for-gilead sciences-syndax-astrazeneca

Gilead’s Livdelzi FDA Approval for Primary Biliary Cholangitis; Incyte and Syndax’s Niktimvo Approved for Graft-Versus-Host Disease; FDA Lifts Hold on BioNTech and MediLink’s ADC Cancer Trial; FDA Approves IMFINZI for Resectable Lung Cancer; Yutrepia Receives Tentative Approval for PAH and PH-ILD

7-promising-hsv-associated-oncolytic-virus-therapies

7 HSV-associated Oncolytic Virus Therapies in Late and Mid-Stage

Breast Cancer Insights

Breast Cancer Insights: Identifying Symptoms and Protecting Your Health

pharma-news-for-ascendis pharma-novartis-servier

FDA Approves Ascendis Pharma’s YORVIPATH; ARS Pharma Gets FDA Green Light for First Nasal Spray; FDA Rejects Lykos’ MDMA-Assisted PTSD Therapy; Novartis’ FABHALTA Receives FDA Accelerated Approval; Servier Snags FDA Approval for Voranigo

Roche’s HER2-Positive Breast Cancer Treatment Franchise

7 Most Common Myths About Breast Cancer Demystified

7 Most Common Myths About Breast Cancer Demystified

tecelra-for-synovial-sarcoma-treatment

TECELRA Approval for Synovial Sarcoma Treatment – A Ray of Hope

HR+HER2- Breast Cancer Feature

Novel Insights Into New Therapies for HR+/HER2- Breast Cancer

Key Facts to Know About Triple-Negative Breast Cancer

Key Facts to Know About Triple-Negative Breast Cancer in Breast Cancer Awareness Month

ER+ Breast Cancer

The Evolving Landscape of ER+ Breast Cancer Treatments

HR+HER2- Breast Cancer Feature

HR+/HER2- Breast Cancer: Unveiling the Worldwide Advances and Strategies

HR+ HER2-Breast Cancer

How HR+/ HER2-Breast Cancer Emerging Drugs Will Transform The Market?

HER2-Positive Breast Cancer

Metastatic HER2-Positive Breast Cancer Landscape: What You Need to Know

8-promising-adenovirus-associated-oncolytic-virus-therapies

8 Late and Mid Stages Adenovirus-associated Oncolytic Virus Therapies To Watch Out

pharma-news-for-Adaptimmune-GSK-Otsuka

Tecelra by Adaptimmune: First FDA-Approved Engineered Cell Therapy for Solid Tumors; GSK’s JEMPERLI Approved for Endometrial Cancer; MBX Biosciences Secures $63.5M in Series C for PEP™ Platform; FDA Stops Actinium’s Radiotherapy Blood Cancer Plans, Pushing Partnering Shift; Otsuka Acquires Jnana for Up to $1.1B, Enhancing Drug Discovery

Subscribe to our Updates

DelveInsight is dedicated to safeguarding your data. We ensure that your information is handled in compliance with relevant data privacy legislation, our internal guidelines, and our privacy policy.

Receive recent Healthcare updates directly in your inbox.

Daily

Weekly

Monthly